AAAAAA

   
Results: 1-2 |
Results: 2
Disease-free survival advantage of adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with node-negative, rapidly proliferating breast cancer: A randomized multicenter study
Authors: Amadori, D Nanni, O Marangolo, M Pacini, P Ravaioli, A Rossi, A Gambi, A Catalano, G Perroni, D Scarpi, E Giunchi, DC Tienghi, A Becciolini, A Volpi, A
Citation: D. Amadori et al., Disease-free survival advantage of adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with node-negative, rapidly proliferating breast cancer: A randomized multicenter study, J CL ONCOL, 18(17), 2000, pp. 3125-3134
Schedule-dependent interaction of doxorubicin, paclitaxel and gemcitabine in human breast cancer cell lines
Authors: Zoli, W Ricotti, L Barzanti, F Dal Susino, M Frassineti, GL Milandri, C Giunchi, DC Amadori, D
Citation: W. Zoli et al., Schedule-dependent interaction of doxorubicin, paclitaxel and gemcitabine in human breast cancer cell lines, INT J CANC, 80(3), 1999, pp. 413-416
Risultati: 1-2 |